<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002622</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-II-02</org_study_id>
    <nct_id>NCT04002622</nct_id>
  </id_info>
  <brief_title>Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma</brief_title>
  <official_title>A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which
      prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell
      activity, thus enhancing immune response and has potential to treat various types of tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>TTR defined as time from the first dose to the first assessment of PR or CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)</condition>
  <arm_group>
    <arm_group_label>TQB2450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Histologically confirmed relapsed or refractory primary mediastinal large B-cell
             lymphoma.

             2. 18 and 75 years; Eastern Cooperative Oncology Group (ECOG) performance status score
             of 0 or 1; Life expectancy &gt; 3 months.

             3. At least one measurable lesion. 4. Left ventricular ejection fraction (LVEF)
             measured by the cardiac echocardiography ≥ 50%.

             5. Screening laboratory values must meet the following criteria:hemoglobin ≥ 80 g/L;
             neutrophils ≥ 1.5*10^9/L; platelets ≥ 100 x 10^9/ L.

             6. Understood and signed an informed consent form.

        Exclusion Criteria:

          -  1. Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Abm or its
             components.

             2. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, or
             anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody ,or any other
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

             3. Has received chemotherapy, surgery, radiotherapy, the last treatment from the first
             dose less than 4 weeks, or oral targeted drugs for less than 5 half-lives, or oral
             fluorouracil pyridine drugs for less than 14 days, mitomycin C and nitrosourea for
             less than 6 weeks.

             4. Has received emergency cytoreductive surgery to control tumors. 5. Has received
             allogeneic hematopoietic stem cell transplantation within the last 5 years.

             6. Has adverse events caused by previous therapy except alopecia that did not recover
             to ≤grade 1.

             7. Has diagnosed and/or treated additional malignancy within 5 years prior to
             randomization. Exceptions include basal cell skin cancer, squamous cell carcinoma of
             skin, melanoma skin and cancer carcinoma in situ of the cervix.

             8. Has definite central nervous system (CNS) infiltration of lymphoma, including brain
             parenchyma, meningeal invasion or spinal cord compression.

             9. Has any active autoimmune disease or a history of autoimmune disease. 10. Has
             serious or uncontrolled diseases such as history of chronic heart failure.

             11. Has any active autoimmune disease or a history of autoimmune disease. 12. Has
             received blood transfusion, erythropoietin granulocyte colony stimulating factor(G
             -CSF)，or Granulocyte macrophage colony stimulating factor(GM-CSF) within 4 weeks
             before the first dose.

             13. Has vaccinated with vaccines or attenuated vaccines within 4 weeks before the
             first dose.

             14. Has received surgery, or unhealed wounds within 4 weeks before the first dose.

             15. Has Hepatic, renal, blood coagulation dysfunction. 16. Has interstitial lung
             disease or non-infectious pneumonia and present residual lesions.

             17. Has received systemic treatment for active infection before the first dose.

             18. Has active or latent tuberculosis. 19. Hepatitis B virus surface antigen (HBsAg)
             positive, and hepatitis B virus DNA copy number &gt; upper limit of normal.

             20. Human immunodeficiency virus antibody positive , hepatitis C antibody (HCV-Ab) and
             hepatitis C virus DNA copy number &gt; upper limit of normal.

             21. Breastfeeding or pregnant women. 22. According to the judgement of the
             researchers, there are other factors that subjects are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daobin Zhou, Doctor</last_name>
    <phone>010-65295564</phone>
    <email>zhoudb@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanyun Ren, Doctor</last_name>
      <phone>13910091592</phone>
      <email>renhy0813@163.com</email>
    </contact>
    <investigator>
      <last_name>Hanyun Ren, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fifth Medical Center of the Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hang Su, Doctor</last_name>
      <phone>13701396736</phone>
      <email>suhang307@126.com</email>
    </contact>
    <investigator>
      <last_name>Hang Su, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daobin Zhou, Doctor</last_name>
      <phone>010-65295564</phone>
      <email>zhoudb@pumch.cn</email>
    </contact>
    <investigator>
      <last_name>Daobin Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijin</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongmei Jing, Doctor</last_name>
      <phone>13661112910</phone>
      <email>hongmei_jing@163.com</email>
    </contact>
    <investigator>
      <last_name>Hongmei Jing, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Hospital</name>
      <address>
        <city>Beijin</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Liu, Doctor</last_name>
      <phone>13520618812</phone>
      <email>liuhui8140@126.com</email>
    </contact>
    <investigator>
      <last_name>Hui Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Medical College Hospital Affiliated to Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianda Hu, Doctor</last_name>
      <phone>13959169016</phone>
      <email>drjiandahu@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianda Hu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiming Li, Doctor</last_name>
      <phone>13719189172</phone>
      <email>lzmsysu@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhiming Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Harbin Medical University</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, Doctor</last_name>
      <phone>13313612989</phone>
      <email>sy86298276@163.com</email>
    </contact>
    <investigator>
      <last_name>Qingyuan Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keshu Zhou, Doctor</last_name>
      <phone>13674902391</phone>
      <email>drzhouks77@163.com</email>
    </contact>
    <investigator>
      <last_name>Keshu Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kai Sun, Doctor</last_name>
      <phone>18237110038</phone>
      <email>ssskkk1112000@163.com</email>
    </contact>
    <investigator>
      <last_name>Kai Sun, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Canser Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Zhou, Doctor</last_name>
      <phone>13975879796</phone>
      <email>Zhouhui9403@126.com</email>
    </contact>
    <investigator>
      <last_name>Hui Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sujun Gao, Doctor</last_name>
      <phone>15843073208</phone>
      <email>sujung1963@163.com</email>
    </contact>
    <investigator>
      <last_name>Sujun Gao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Li, Doctor</last_name>
      <phone>13998898232</phone>
      <email>liyanz@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yan Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming Hou, Doctor</last_name>
      <phone>18560087028</phone>
      <email>yan_yxzdtq@163.com</email>
    </contact>
    <investigator>
      <last_name>Ming Hou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongguo Zhao, Doctor</last_name>
      <phone>18661809195</phone>
      <email>zhao6201@126.com</email>
    </contact>
    <investigator>
      <last_name>Hongguo Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Li, Doctor</last_name>
      <phone>13564181131</phone>
      <email>lilyforever76@126.com</email>
    </contact>
    <investigator>
      <last_name>Ping Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Tumor Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fangfang Lv, Doctor</last_name>
      <phone>18017312613</phone>
      <email>lvff80@163.com</email>
    </contact>
    <investigator>
      <last_name>Fangfang Lv, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Tumor Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haiyan Yang, Doctor</last_name>
      <phone>13857182590</phone>
      <email>haiyanyang1125@163.com</email>
    </contact>
    <investigator>
      <last_name>Haiyan Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

